Medical pioneers Carl June, Bruce Levine, and Drew Weissman have teamed up to launch a new biotech that hopes to use the industry’s buzziest technologies to boost the beleaguered cell therapy field.
Their new venture, Capstan Therapeutics, launched Wednesday with a combined $165 million in seed and Series A financing.
Click this link for the original source of this article.
Author: Allison DeAngelis
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.